Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells

J Am Acad Dermatol. 2021 Apr;84(4):1086-1089. doi: 10.1016/j.jaad.2020.07.069. Epub 2020 Jul 21.

Authors

Onat Kadioglu¹, Mohamed E M Saeed¹, Henry J Greten², Katharina Mayr¹, David Schrama³, Wynand P Roos⁴, Thomas Efferth⁵

Affiliations

¹ Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
² Heidelberg Clinics for Integrative Diagnostics, Heidelberg, Germany.
³ Department of Dermatology, Julius-Maximilian University, Würzburg, Germany.
⁴ Institute of Toxicology, Medical University Center, Mainz, Germany.
⁵ Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: efferth@uni-mainz.de.

PMID: 32707252
DOI: 10.1016/j.jaad.2020.07.069

No abstract available

MeSH terms

Amino Acid Substitution
Cell Line, Tumor
Dose-Response Relationship, Drug
Drug Design
Drug Repositioning
Drug Screening Assays, Antitumor
Humans
Inhibitory Concentration 50
Melanoma / drug therapy*
Melanoma / enzymology
Models, Molecular
Molecular Docking Simulation
Molecular Targeted Therapy*
Mutation, Missense
Neoplasm Proteins / antagonists & inhibitors*
Neoplasm Proteins / chemistry
Neoplasm Proteins / genetics
Point Mutation
Precision Medicine
Protein Conformation
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / isolation & purification
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / chemistry
Proto-Oncogene Proteins B-raf / genetics
Structure-Activity Relationship

Substances

Neoplasm Proteins
Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf